FDA Cancels Telavancin Advisory Panel Review 3 Days Before Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Data submitted by Theravance/Astellas in response to an October FDA “approvable” letter for the antibiotic could be behind the agency’s decision.
You may also be interested in...
Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.
Theravance’s Telavancin Data Integrity Issues Resolved; FDA Review Back On Track
FDA will resume the review of Theravance’s antibiotic telavancin at a three-day advisory committee meeting in November after completing an audit of the company’s clinical trial data.
FDA Plans Further Audits Of Telavancin Study Sites; No Major Problems To Date
Firm says FDA and company audits of telavancin clinical trial data are progressing well; no predictions on how long process may take.